This subproject is one of many research subprojects utilizing theresources provided by a Center grant funded by NIH/NCRR. The subproject andinvestigator (PI) may have received primary funding from another NIH source,and thus could be represented in other CRISP entries. The institution listed isfor the Center, which is not necessarily the institution for the investigator.
SPECIFIC AIMS Primary Endpoints:1. To determine the tumor response rate of AIDS-related Kaposi's sarcoma to topical halofuginone versus vehicle control.2. To evaluate the safety and tolerability of topical halofuginone and vehicle patients with AIDS-related Kaposi's sarcoma.Secondary Endpoints:1. To determine the ability of topical halofuginone to inhibit expression of MMP-2 and Collagen type I in AIDA-related Kaposi's sarcoma.2. To explore the relationship between baseline CD4 and CD8 counts, HIV viral load and HHV-8 viral load and response to halofuginone.
Showing the most recent 10 out of 1085 publications